About Event

Industry’s Only Gene Therapy Vector Development Meeting

The 4th Next Generation Gene Therapy Vectors Summit played host to cutting-edge talks, interactive group discussions, and expert panel discussions, leaving attendees with the actionable data and insights needed to increase the specificity, tissue and cell targeting, packaging capacity, and safety profiles of their vector platforms.

Biopharma heavyweights such as 4D Molecular Therapeutics, Alexion Pharmaceuticals, and Voyager Therapeutics joined boundary pushing groups and academics, with the likes of Avista Therapeutics, Code Biotherapeutics, and the Deverman Lab sharing brand new data and technologies with attendees.

Keeping the finger on the pulse of novel vector development efforts, this expert hub addressed the following bottlenecks facing industry in 2024:

Next_Generation_Gene_Therapy_Vector_Summit_2023

Capsid Discovery and engineering work: improving tissue and cell targeting, evading the immune system, and exploring machine-guided design

Next_Generation_Gene_Therapy_Vector_Summit_2023

Payload Design: levelling up cassette engineering and enabling controllable transgene expression to improve safety and expression profiles

Next_Generation_Gene_Therapy_Vector_Summit_2023

Scalable and Cost-Effective Manufacturability: unlocking productive manufacturability downstream through smart vector development and selection upstream

Next_Generation_Gene_Therapy_Vector_Summit_2023
Next_Generation_Gene_Therapy_Vector_Summit_2023

Beyond AAV: leveraging translatable vector development insights from disruptive viral and non-viral delivery platforms

Immunogenicity and Toxicity Concerns: overcoming immune responses to IV-administered AAV vectors with improved capsid engineering, payload design, and tissue tropism validation efforts

Additionally, key business development leaders from industry joined us for facilitated networking sessions, fostering partnerships and collaborations, conducting market intelligence, and uncovering potential new business opportunities to inform their long-term strategic decision making.

The ultimate roadmap for learning how to innovate gene therapy vector capsid and payload design, join us next year to supercharge your vector platform and unlock business opportunities for the future.

Who Attended?

70 senior industry figures from the gene therapy field joined us in 2024.

Well-established now as the industry-leading event for showcasing the latest innovation and advances in gene therapy vector development, the 4th Next Generation Gene Therapy Vectors Summit provided an opportunity for 70 experts, at the forefront of the field, to connect, learn, and collaborate.

All in all, over 40 organizations joined us, with both technical content and business development leaders in the room from the likes of:

Register Interest
Partner